Insider · CIK 0002073624
Namrata Saroj
Files at OCUL (OCULAR THERAPEUTIX, INC). First filing Nov 7, 2025, latest Nov 7, 2025.
Namrata Saroj files SEC Form 4 as officer at OCUL (OCULAR THERAPEUTIX, INC). Since Nov 7, 2025, Namrata Saroj has reported 0 open-market buys worth $0 and 1 open-market sell worth $278k, the latest filed on Nov 7, 2025.
A track record needs three past buys with six months of prices behind them; Namrata Saroj has 0, so none is measured yet.
The newest scored trade: sold $278k of OCUL on Nov 5, 2025, filed Nov 7, 2025, scored 14 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $278k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OCUL: OCULAR THERAPEUTIX, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | OCULAR THERAPEUTIX, INC | $278k 25,865 shares | -13% | +82% from low-21% from high |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 254,620 | Jan 6, 2026 |
| Jan 2, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Nov 5, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -25,865 | $10.74 | $278k | 174,135 | Nov 7, 2025 |
Questions about Namrata Saroj
Answered from the filings on this page, as of the latest one.
Is Namrata Saroj buying or selling?
In the last 12 months Namrata Saroj reported 0 open-market buys worth $0 and 1 open-market sell worth $278k on SEC Form 4; the latest was sold $278k of OCUL on Nov 5, 2025. Grants, option exercises and tax withholding are not counted.
How did Namrata Saroj's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Namrata Saroj has 0.
Where does Namrata Saroj file Form 4?
Namrata Saroj has filed Form 4 at OCUL (OCULAR THERAPEUTIX, INC) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.